NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2.64	3.54	11.06	0.7	0.9
Short-Term Investments	0	3.55	0	0	0
Cash & Cash Equivalents	2.64	7.09	11.06	0.7	0.9
Cash Growth	-62.76%	-35.91%	1482.69%	-21.90%	-
Receivables	0.24	0.26	0.31	0.03	0.02
Other Current Assets	0.04	0.04	0.04	0.04	0
Total Current Assets	2.92	7.38	11.41	0.77	0.91
Property, Plant & Equipment	0.24	0.31	0.02	0.01	0.01
Other Long-Term Assets	0.02	0.02	0	0	0.04
Total Long-Term Assets	0.26	0.33	0.02	0.01	0.04
Total Assets	3.18	7.71	11.43	0.78	0.96
Accounts Payable	3.46	1.73	0.6	0.12	0.04
Total Current Liabilities	3.46	1.73	0.6	0.12	0.04
Long-Term Debt	0.07	0.15	0	0	0
Other Long-Term Liabilities	1.52	0.22	1.83	0	0
Total Long-Term Liabilities	1.59	0.37	1.83	0	0
Total Liabilities	5.05	2.09	2.43	0.12	0.04
Total Debt	0.07	0.15	0	0	0
Debt Growth	-50.34%	-	-	-	-
Retained Earnings	-32.07	-20.79	-8.45	-4.41	-1.58
Shareholders' Equity	-1.87	5.62	9.01	0.66	0.92
Net Cash / Debt	2.57	6.94	11.06	0.7	0.9
Net Cash / Debt Growth	-63.03%	-37.24%	1482.69%	-21.90%	-
Net Cash Per Share	-	0.60	1.77	0.13	0.19
Working Capital	-0.54	5.66	10.82	0.65	0.88
Book Value Per Share	-0.15	0.49	1.44	0.12	0.20

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).